A comprehensive universal carrier screening panel screens for variations in 400+ genes known to be associated with genetic disorders, such as congenital adrenal hyperplasia (CAH) and spinal muscular atrophy (SMA).

As the world’s first molecular blood test for early detection of gastric cancer, GASTROClear is an HSA-approved Class C medical device that was launched as an IVD product in Singapore in 2019. It provides information on your risk of gastric cancer, and you can then manage your risks via regular screening for early detection, where treatment is more effective and less costly.

Hereditary cancer testing is key to identifying patients and families who may be at increased risk of developing certain types of cancer, so actions can be taken for detection and prevention.